Alpine Immune Sciences, Inc.

NasdaqGM:ALPN Rapport sur les actions

Capitalisation boursière : US$4.5b

Alpine Immune Sciences Bilan de santé

Santé financière contrôle des critères 6/6

Alpine Immune Sciences possède un total de capitaux propres de $332.7M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $373.6M et de $40.9M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$305.66m
Fonds propresUS$332.70m
Total du passifUS$40.94m
Total des actifsUS$373.65m

Mises à jour récentes de la santé financière

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21
Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23
We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

May 11
Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Dec 12
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Sep 20

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09
Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12
Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18
Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18
Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ALPN ( $308.3M ) dépassent ses passifs à court terme ( $32.2M ).

Passif à long terme: Les actifs à court terme de ALPN ( $308.3M ) dépassent ses passifs à long terme ( $8.7M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: ALPN est sans dette.

Réduire la dette: ALPN n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 6.6%.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ALPN dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ALPN dispose d'une marge de trésorerie suffisante pour 2.4 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 21.4 % chaque année.


Découvrir des entreprises saines